English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tedizolid is a novel, expanded-spectrum oxazolidinone with potent activity against a wide range of Gram-positive pathogens. A total of 425 isolates of Gram-positive bacteria were obtained consecutively from patients with acute bacterial skin and skin structure infections (ABSSSIs) or pneumonia. These isolates included methicillin-susceptibleStaphylococcus aureus (MSSA) (n = 100), methicillin-resistantStaphylococcus aureus (MRSA) (n = 100),Streptococcus pyogenes (n = 50),Streptococcus agalactiae (n = 50),Streptococcus anginosus group (n = 75),Enterococcus faecalis (n = 50), and vancomycin-resistant enterococci (VRE) (Enterococcus faecium ) (n = 50). The MICs of tedizolid and linezolid were determined by the agar dilution method. Tedizolid exhibited betterin vitro activities than linezolid against MSSA (MIC90 s, 0.5 versus 2 μg/ml), MRSA (MIC90 s, 0.5 versus 2 μg/ml),S. pyogenes (MIC90 s, 0.5 versus 2 μg/ml),S. agalactiae (MIC90 s, 0.5 versus 2 μg/ml),Streptococcus anginosus group (MIC90 s, 0.5 versus 2 μg/ml),E. faecalis (MIC90 s, 0.5 versus 2 μg/ml), and VRE (MIC90 s, 0.5 versus 2 μg/ml). The tedizolid MICs againstE. faecalis (n = 3) and VRE (n = 2) intermediate to linezolid (MICs, 4 μg/ml) were 1 μg/ml and 0.5 μg/ml, respectively. The tedizolid MIC90 s against S. anginosus ,S. constellatus , andS. intermedius were 0.5, 1, and 0.5 μg/ml, respectively, and the rates of susceptibility based on the U.S. FDA MIC interpretive breakpoints to the isolates were 16%, 28%, and 72%, respectively. Tedizolid exhibited 2- to 4-fold betterin vitro activities than linezolid against a variety of Gram-positive cocci associated with ABSSSIs and pneumonia. The lower susceptibilities of tedizolid against isolates ofS. anginosus andS. constellatus than against those ofS. intermedius in Taiwan were noted.

antimicrobial agents and chemotherapy

<i>In Vitro</i> Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia

In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia